Ito K, Izawa K, Tanaka Y, Kogure K, Saito T
Jpn J Antibiot. 1976 Feb;29(2):189-96.
This paper describes briefly the results obtained with AMPC (Pasetocin) administered by oral route to 21 patients with infection of the respiratory tract. 1. There was no difference in therapeutic effect on infection of the respiratory tract between daily dosages of 1,000 mg and 750 mg (the former was orally given in 4 divided doses every 6 hours a day and the latter in 3 divided doses after meal). The response of the patients to AMPC was remarkable or satisfactory. 2. Acute aggravation symptoms associated with chronic infection of the respiratory tract showed similar improvement to single acute infection of the respiratory tract. 3. The patients presenting acute aggravation symptoms received treatment for chronic stage consisting of consecutive oral administration of AMPC (500 approximately 750 mg a day) and their prognosis was favorable. Side effects attributable to prolonged treatment were not noted. 4. The incidence of side effects can be reduced largely by rejecting form AMPC therapy the patients who are hypersensitive to drugs including penicillins.
本文简要描述了对21例呼吸道感染患者口服氨比西林（派士托星）所取得的结果。1. 每日剂量1000毫克和750毫克对呼吸道感染的治疗效果无差异（前者每天分4次，每6小时口服一次，后者饭后分3次服用）。患者对氨比西林的反应显著或令人满意。2. 与呼吸道慢性感染相关的急性加重症状与单纯呼吸道急性感染的改善情况相似。3. 出现急性加重症状的患者接受了氨比西林连续口服（每日约500至750毫克）的慢性期治疗，预后良好。未发现因长期治疗引起的副作用。4. 通过排除对包括青霉素在内的药物过敏的患者接受氨比西林治疗，可大大降低副作用的发生率。
